Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus cadonilimab in advanced or metastatic hepatocellular carcinoma after first-line failure
ChiCTR2600120728Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and cadonilimab in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Primary endpoint: progression-free survival. Started Mar 2026; status: recruiting.
02
Drugs
regorafenibcadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600120728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120728.